Oric Pharmaceuticals预计首个三期试验Himalayas-1将于2026年上半年启动,针对阿比特龙治疗后MCRPC患者

美股速递
Apr 01

Oric Pharmaceuticals Inc. 宣布,其首个三期临床试验——代号为Himalayas-1的研究——预计将在2026年上半年正式启动。该试验将专注于治疗转移性去势抵抗性前列腺癌(MCRPC)患者,这些患者先前已接受过阿比特龙的治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10